Post-translational modifications, a key process in CD36 function: lessons from the spontaneously hypertensive rat heart - PubMed (original) (raw)
doi: 10.1016/j.yjmcc.2011.04.001. Epub 2011 Apr 13.
Clémence Merlen, Fanny Vaillant, Janie McDuff, Bertrand Bouchard, Pauline C Beguin, Vernon W Dolinsky, Sylvain Foisy, Louis R Villeneuve, François Labarthe, Jason R B Dyck, Bruce G Allen, Guy Charron, Christine Des Rosiers
Affiliations
- PMID: 21510957
- DOI: 10.1016/j.yjmcc.2011.04.001
Post-translational modifications, a key process in CD36 function: lessons from the spontaneously hypertensive rat heart
Benjamin Lauzier et al. J Mol Cell Cardiol. 2011 Jul.
Abstract
CD36, a multifunctional protein, is involved in cardiac long chain fatty acid (LCFA) metabolism and in the etiology of heart diseases, yet the functional impact of Cd36 gene variants remains unclear. In 7-week-old spontaneously hypertensive rats (SHR), which, like humans, carry numerous mutations in Cd36, we tested the hypothesis that their restricted cardiac LCFA utilization occurs prior to hypertrophy due to defective CD36 post-translational modifications (PTM), as assessed by ex vivo perfusion of (13)C-labeled substrates and biochemical techniques. Compared to their controls, SHR hearts displayed a lower (i) contribution of LCFA to β-oxidation (-40%) and triglycerides (+2.8 folds), which was not explained by transcriptional changes or malonyl-CoA level, a recognized β-oxidation inhibitor, and (ii) membrane-associated CD36 protein level, but unchanged distribution. Other results demonstrate alterations in CD36 PTM in SHR hearts, specifically by N-glycosylation, and the importance of O-linked-β-N-acetylglucosamine for its membrane recruitment and role in LCFA use in the heart.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats.
Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Aitman TJ, et al. Nat Genet. 1999 Jan;21(1):76-83. doi: 10.1038/5013. Nat Genet. 1999. PMID: 9916795 - Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.
Luiken JJ, Niessen HE, Coort SL, Hoebers N, Coumans WA, Schwenk RW, Bonen A, Glatz JF. Luiken JJ, et al. Biochem J. 2009 Apr 15;419(2):447-55. doi: 10.1042/BJ20082159. Biochem J. 2009. PMID: 19138173 - Induction of Cd36 expression elicited by fish oil PUFA in spontaneously hypertensive rats.
Alexander Aguilera A, Hernández Díaz G, Lara Barcelata M, Angulo Guerrero O, Oliart Ros RM. Alexander Aguilera A, et al. J Nutr Biochem. 2006 Nov;17(11):760-5. doi: 10.1016/j.jnutbio.2005.12.007. Epub 2006 Feb 3. J Nutr Biochem. 2006. PMID: 16517147 - Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview.
Holloway GP, Luiken JJ, Glatz JF, Spriet LL, Bonen A. Holloway GP, et al. Acta Physiol (Oxf). 2008 Dec;194(4):293-309. doi: 10.1111/j.1748-1716.2008.01878.x. Epub 2008 Jul 9. Acta Physiol (Oxf). 2008. PMID: 18510711 Review. - New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36.
Brinkmann JF, Abumrad NA, Ibrahimi A, van der Vusse GJ, Glatz JF. Brinkmann JF, et al. Biochem J. 2002 Nov 1;367(Pt 3):561-70. doi: 10.1042/BJ20020747. Biochem J. 2002. PMID: 12088505 Free PMC article. Review.
Cited by
- Role of _O_-Linked _N_-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology.
Chatham JC, Zhang J, Wende AR. Chatham JC, et al. Physiol Rev. 2021 Apr 1;101(2):427-493. doi: 10.1152/physrev.00043.2019. Epub 2020 Jul 30. Physiol Rev. 2021. PMID: 32730113 Free PMC article. Review. - Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.
Ismael S, Purushothaman S, Harikrishnan VS, Nair RR. Ismael S, et al. Mol Cell Biochem. 2015 Aug;406(1-2):173-82. doi: 10.1007/s11010-015-2435-x. Epub 2015 May 15. Mol Cell Biochem. 2015. PMID: 25976666 - The role of CD36 in cardiovascular disease.
Shu H, Peng Y, Hang W, Nie J, Zhou N, Wang DW. Shu H, et al. Cardiovasc Res. 2022 Jan 7;118(1):115-129. doi: 10.1093/cvr/cvaa319. Cardiovasc Res. 2022. PMID: 33210138 Free PMC article. Review. - Multiphasic triacylglycerol dynamics in the intact heart during acute in vivo overexpression of CD36.
Carley AN, Bi J, Wang X, Banke NH, Dyck JR, O'Donnell JM, Lewandowski ED. Carley AN, et al. J Lipid Res. 2013 Jan;54(1):97-106. doi: 10.1194/jlr.M029991. Epub 2012 Oct 25. J Lipid Res. 2013. PMID: 23099442 Free PMC article. - The anti-TNF-α antibody infliximab inhibits the expression of fat-transporter-protein FAT/CD36 in a selective hepatic-radiation mouse model.
Martius G, Cameron S, Rave-Fränk M, Hess CF, Wolff HA, Malik IA. Martius G, et al. Int J Mol Sci. 2015 Mar 2;16(3):4682-97. doi: 10.3390/ijms16034682. Int J Mol Sci. 2015. PMID: 25739082 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical